Enodia

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Kymera Therapeutics

This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Kesmalea Therapeutics

This drug discovery company develops oral, central nervous system penetrant protein degraders to treat oncology and neurological diseases.

EpiBiologics

This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.